Last updated: April 13, 2026
What is the nature of the litigation?
AZURITY Pharmaceuticals, Inc. filed a patent infringement lawsuit against Amneal Pharmaceuticals LLC in the United States District Court for the Southern District of New York. The case, numbered 1:21-cv-08717, alleges that Amneal's generic drug products infringe multiple AZURITY patents related to a proprietary formulation.
What patents are involved?
AZURITY claims that Amneal’s generic versions of the drug infringe on several patents, primarily:
- U.S. Patent No. 10,727,123: Covering the formulation’s composition.
- U.S. Patent No. 10,850,344: Covering specific processing methods.
The patents' expiration dates are anticipated in 2032 and 2033, respectively.
What are the key allegations?
AZURITY asserts that Amneal's generic products infringe on its patents through:
- Use of the same active pharmaceutical ingredient (API) combination.
- Similar manufacturing processes that infringe on the process patents.
The complaint emphasizes that Amneal launched the product before patent expiration, violating patent rights.
What procedural steps have been taken?
- The complaint was filed on December 1, 2021.
- Amneal filed a motion to dismiss on April 15, 2022, arguing that the patents are invalid and that the infringement claim lacks specific evidence.
- AZURITY opposed the motion on June 1, 2022, providing detailed infringement analyses.
- The court held a preliminary conference on August 3, 2022, setting discovery timelines.
What is the current status?
As of the latest update in Q1 2023:
- The court has denied Amneal's motion to dismiss, allowing the case to proceed.
- Both parties are engaged in discovery, focusing on patent validity and infringement evidence.
- A trial date has been tentatively scheduled for late 2024.
Industry implications
- The case exemplifies the ongoing tensions in generic drug markets over patent rights.
- Successful infringement claims could delay Amneal’s product launch, impacting market share.
- Conversely, if Amneal establishes patent invalidity, AZURITY's patents may be compromised.
Comparative context
- Similar litigation involves other pharmaceutical companies defending patents against generic challengers, such as Teva vs. Sandoz and Eli Lilly vs. Watson.
- Patent validity challenges are common in the pharmaceutical industry, often resolved through settlement or patent invalidation rather than trial.
Key legal issues
- Patent validity: Whether the asserted patents meet Federal Circuit standards.
- Infringement: Whether Amneal’s generic product infringe the claims.
- Paragraph IV certifications: Amneal may have filed an ANDA with paragraph IV certifications, prompting patent litigation.
Financial impact considerations
- AZURITY's litigation success may preserve market exclusivity.
- Amneal’s potential to obtain a market entry license depends on patent challenges.
- Patent litigation duration and costs could influence pricing strategies and market launch timelines.
Key Takeaways
- The case centers on patent infringement claims over proprietary formulation and manufacturing processes.
- Amneal’s defense hinges on patent invalidity and non-infringement arguments.
- The legal process is progressing with discovery, pending trial in late 2024.
- Patent litigation remains a common barrier for generic drug entry, with significant market implications.
- Recent court rulings favor the continuation of the case, indicating a high-stakes contest.
Frequently Asked Questions
1. What is the significance of paragraph IV certifications?
Paragraph IV certifications allow generic manufacturers to challenge patents by asserting the claims are invalid or not infringed. Filing such certifications typically triggers patent litigation.
2. How long does a patent infringement case usually last?
Patent infringement cases in pharmaceutical contexts typically extend over 2-3 years from filing to trial, depending on case complexity and procedural motions.
3. Can patent invalidity claims be proved during litigation?
Yes. Patents can be invalidated if the defendant demonstrates they do not meet legal requirements such as novelty, non-obviousness, or adequate disclosure.
4. What are the potential market consequences if AZURITY loses the case?
AZURITY could lose exclusivity rights, allowing generics like Amneal to market similar products earlier than anticipated, reducing revenue.
5. How does this case compare to other patent disputes in pharma?
It is similar to cases involving prominent litigants, featuring challenges to patent validity and infringement, which are routine in pharmaceutical patent enforcement.
References:
[1] U.S. District Court for the Southern District of New York. (2021). AZURITY Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC. Case No. 1:21-cv-08717.
[2] United States Patent and Trademark Office. (2022). Patent exam rules and litigation procedures.
[3] FDA. (2021). ANDA approval process and patent challenges.
